生成式AI市场格局重塑 - 谷歌旗下Gemini在生成式AI网络流量份额实现显著跃升 从5.4%增长至18.2% 增幅超过三倍[2] - 行业先驱ChatGPT的市场主导地位大幅下滑 份额从87.2%降至68.0% 下降了19个百分点[3] - 市场分析认为这标志着明确的“接管弧” 行业正从初始炒作阶段进入谷歌基础设施优势显现的阶段[3] 谷歌Gemini增长的核心驱动力 - 增长主要得益于谷歌的“原生分发”优势 Gemini深度集成于Chrome、Android、Workspace和Search等用户高频使用的现有生态中[4] - 这种集成在AI使用从新奇转向日常工具时成为关键差异化因素 能自然“捕获流量” 通过减少切换应用的摩擦来吸引用户[4] - 尽管分发渠道重要 但产品信任更为关键 与微软Copilot份额停滞形成对比 Gemini成功将其广泛触达转化为用户习惯[5][6] 公司股价表现 - Alphabet的C类股股价在2025年表现强劲 年初至今上涨65.59% 过去一年上涨60.16% 远超纳斯达克100指数同期22.31%和17.86%的涨幅[7] - 近期股价在近六个月上涨80.97% 但在近一个月内下跌1.44% 周三收盘价基本持平 微跌0.0032%至每股315.67美元[7]

Seattle, Washington-based Starbucks Corporation (SBUX) is the world’s largest specialty coffee roaster and retailer. With a global footprint of tens of thousands of stores across more than 87 countries, it currently holds a market cap of $96.2 billion. Founded in 1971, Starbucks operates primarily through company-operated and licensed retail stores offering premium coffee, espresso beverages, teas, food items, packaged goods, and merchandise under brands such as Starbucks Coffee, Teavana, Seattle’s Best Co ...

Steel Dynamics, Inc. (STLD), headquartered in Fort Wayne, Indiana, functions as a leading steel producer and metal recycler. Valued at $25.6 billion by market cap, the company’s products include flat rolled steel sheet, engineered bar, special-bar-quality, and structural beams. It also recycles scrap metal and manufactures non-residential building components, including steel joists, girders, trusses, and decks, for construction projects. The leading domestic steel producer and metals recycler is expected t ...

Social Security tax rules will change in 2026.Getty Images; Tyler Le/BI Social Security tax rules will change in 2026 at the state and federal level. West Virginia will stop taxing Social Security benefits, leaving seven states that tax benefits. Older Americans will also see expanded federal tax breaks through 2028. Americans on Social Security could see new federal tax breaks in 2026 — and some states will stop taxing benefit income. The largest social safety net in the US provides monthly paym ...

SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company (”Lilly”).ABL Bio and Lilly are currently conducting joint research and development on multiple therapeutic candidates leveraging the Grabody platform across various mod ...

行业概况 - 2025年制药和生物技术行业表现震荡，在全年大部分时间表现疲软后，过去几个月出现反弹 [2] - 行业反弹可归因于几家大型制药公司与特朗普政府达成药品定价协议后政策改善，以及全行业强劲的并购活动 [2] - 生物技术板块在过去六个月上涨26%，表现优于标普500指数 [2] - 创新可能推动行业增长，肥胖、基因治疗、炎症和神经科学等关键领域吸引了投资者关注 [3] - 监管活动保持健康，截至2025年12月22日，FDA已批准44种新疗法 [3] - 预计2026年并购活动将保持强劲 [3] Mineralys Therapeutics (MLYS) - 公司是一家临床阶段生物技术公司，开发其主要候选产品lorundrostat，一种口服、高选择性醛固酮合酶抑制剂，用于治疗未控制的高血压、耐药性高血压、慢性肾病和阻塞性睡眠呼吸暂停 [5] - 2025年上半年，lorundrostat在未控制或耐药性高血压患者中的关键III期Launch-HTN研究和II期Advance-HTN研究均达到主要疗效终点，具有统计学意义，并显示出良好的安全性和耐受性 [6] - 公司报告了II期Explore-CKD研究的积极顶线数据，显示lorundrostat联合SGLT2抑制剂可显著改善高血压合并慢性肾病患者的预后 [7] - 基于这些数据，公司计划在2026年初提交lorundrostat的新药申请 [7] - 公司已完成lorundrostat治疗伴有高血压的中重度阻塞性睡眠呼吸暂停超重或肥胖参与者的II期Explore-OSA研究入组，顶线数据预计在2026年第一季度公布 [8] - 2025年至今，公司股价大幅上涨203.4% [8] - 过去60天，公司2026年每股亏损预估从3.06美元收窄至2.50美元 [9] Lyell Immunopharma (LYEL) - 公司是一家临床阶段生物技术公司，专注于为血液恶性肿瘤和实体瘤患者开发下一代CAR T细胞疗法 [10][11] - 主要候选产品ronde-cel是一种自体CAR T细胞产品，用于治疗大B细胞淋巴瘤，正在关键性PiNACLE研究（三线或后线治疗）和I/II期研究（二线治疗）中进行评估 [11] - 评估ronde-cel用于二线治疗大B细胞淋巴瘤的第二项关键III期研究预计于2026年初开始 [12] - FDA已授予ronde-cel用于二线及三线或后线治疗复发/难治性大B细胞淋巴瘤的再生医学先进疗法资格 [12] - 公司近期从Innovative Cellular Therapeutics获得了LYL273（一种新型自体鸟苷酸环化酶C靶向CAR T细胞候选产品）的全球（除中国外）权益，该产品正在针对难治性转移性结直肠癌和其他表达GCC的癌症进行早期研究 [13] - LYL273的I期研究早期数据显示，在美国难治性转移性结直肠癌患者中具有剂量依赖性的临床活性，下一次数据更新预计在2026年上半年 [14] - 截至2025年9月30日，公司拥有强劲的现金状况，约3.2亿美元 [14] - 2025年至今，公司股价大幅上涨191.6% [14] - 过去60天，公司2026年每股亏损预估从12.68美元大幅收窄至9.70美元 [15] Insmed (INSM) - 公司目前销售产品Arikayce，该药获批用于治疗难治性鸟分枝杆菌复合体肺部疾病，是公司产品组合中首个上市产品，也是稳定的收入驱动力 [16] - 2025年前九个月，Arikayce销售额为3.145亿美元，同比增长21% [16] - 2025年8月，FDA批准了公司的第二个产品Brinsupri，作为非囊性纤维化支气管扩张症的首个治疗方法，这是一个重大推动 [17] - 该药近期也在欧洲获批用于类似适应症 [17] - 2025年第三季度，Brinsupri销售额为2810万美元，在美国的早期商业发布令人鼓舞，预计势头将持续到2026年 [17] - 公司在本月早些时候遭遇重大挫折，评估Brinsupri用于治疗不伴鼻息肉的慢性鼻窦炎的IIb期BiRCh研究未能达到其主要或次要疗效终点，公司因此决定终止Brinsupri用于该适应症的开发 [18] - 公司还在II期CEDAR研究中评估Brinsupri用于化脓性汗腺炎适应症，顶线数据预计在2026年上半年公布，积极的数据更新应有助于重振因BiRCh研究结果而受挫的投资者信心 [19] - 2025年至今，公司股价大幅上涨156% [19] - 过去60天，公司2026年每股亏损预估从3.65美元收窄至3.58美元 [20] Nektar Therapeutics (NKTR) - 公司是一家临床阶段公司，正在两项独立的IIb期研究中开发其主要候选产品rezpegaldesleukin，分别针对特应性皮炎和斑秃 [21] - 2025年6月公布的REZOLVE-AD研究数据显示，在第16周，rezpeg在所有剂量水平上均比安慰剂显著改善了EASI评分 [22] - 公司管理层认为，EASI评分的快速降低和瘙痒的改善支持了rezpeg作为治疗特应性皮炎的首个和同类最佳免疫调节剂的潜力 [22] - 公司预计在2026年上半年将rezpeg推进至针对特应性皮炎的III期开发 [22] - 本月早些时候，公司宣布rezpeg的REZOLVE-AA研究在重度至非常重度斑秃患者中证明了概念验证，结果支持将rezpeg推进至针对斑秃的III期开发的计划 [23] - 公司认为rezpeg是一种潜在的首个解决疗法，可能解决自身免疫性疾病和炎症性疾病中潜在的免疫系统失衡 [23] - 公司另一候选产品NKTR-255（针对某些癌症适应症开发）的研究也进展顺利，预计不久将有数项数据读出 [24] - 2025年至今，公司股价大幅上涨218.8% [24] - 过去60天，公司2026年每股亏损预估从12.82美元收窄至10.81美元 [25]

Boston, Massachusetts-based BXP, Inc. (BXP) is the largest publicly traded developer, owner, and manager of premier workplaces. Valued at $11 billion by market cap, the company operates as a real estate investment trust (REIT), including properties owned by joint ventures totaling 53.5 million square feet and 186 properties. The REIT is expected to announce its fiscal fourth-quarter earnings for 2025 in the near future. Ahead of the event, analysts expect BXP to report an FFO of $1.80 per share on a dilu ...

The number of High Net Worth Individuals (HNIs) in India is growing significantly, and the growth rate is expected to remain high in the foreseeable future. Financial services companies are launching various products to cater to the financial needs of the HNI category. Banks are also launching various financial products, including premium credit cards for HNIs and other affluent categories.RBL Bank has recently launched two premium credit cards, LUMIÈRE and NOVA, to help curate extraordinary experiences for ...

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index remained in the “Greed” zone on Wednesday.U.S. stocks settled higher on Wednesday, with the Dow Jones index gaining more than 250 points and the S&P 500 hitting fresh records during the session.The New York Stock Exchange closed early at 1 p.m. ET on Wednesday and remained closed Thursday for Christmas Day.Nike (NYSE:NKE) shares benefited after Apple Inc. (NASDAQ:AAPL) CEO Tim Cook disclosed the pu ...

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index remained in the “Greed” zone on Wednesday.U.S. stocks settled higher on Wednesday, with the Dow Jones index gaining more than 250 points and the S&P 500 hitting fresh records during the session.The New York Stock Exchange closed early at 1 p.m. ET on Wednesday and remained closed Thursday for Christmas Day.Nike (NYSE:NKE) shares benefited after Apple Inc. (NASDAQ:AAPL) CEO Tim Cook disclosed the pu ...